Clinical Trials Browser

Phase 1 × Ovarian Neoplasms × aldesleukin × Clear all

NCT03017131 2025-03-28

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02876510 2025-02-04

ACTolog

Phase 1 Completed

GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT03691376 2024-09-19

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Terminated

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02482090 2017-08-16

TIL Therapy for Metastatic Ovarian Cancer

Phase 1 Completed

Ovarian Neoplasms

NCT02470559 2016-02-17

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Phase 1 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00019136 2015-04-29

Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer

Phase 1 Completed

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT01212887 2012-02-28

Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer

Phase 1 Terminated

BreastGastrointestinalGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma